AbbVie Inc. (ABBV) Q3 2026 (USD): Adj. EPS 3.82 (exp. 3.73), Revenue 17.4bln (exp. 17.3bln)

• Adj. EPS 13.95-13.99 (exp. 13.91).

A modest top- and bottom-line beat with a small lift to full-year adjusted EPS guidance is the standard shape of AbbVie's recent reporting cadence, where the equity debate has not been the quarter itself but the pace of the Humira erosion and whether the newer immunology pair, Skyrizi and Rinvoq, is backfilling the revenue base fast enough to sustain the growth narrative. The key tell in prints of this type is the segment mix rather than the headline: beats driven by immunology and oncology tend to be received better than beats driven by aesthetics recovery or one-offs below the operating line, since the market treats the latter as lower-quality. A guidance raise of this size sits in the familiar bracket of conservative guidance-setting, and the established pattern is that attention shifts quickly to the call for the trajectory of the biosimilar hit, pipeline readouts, and any colour on pricing. Guidance that merely brackets consensus rather than clears it has historically limited the magnitude of the post-print move. Single-digit beats on both lines with a raise that keeps consensus near the low end of the range is typically a confirmatory rather than a repricing print for this name.